FDA approves fruquintinib for refractory metastatic colorectal cancer
Takeda's Fruzaqla cleared for adults with mCRC after specific prior chemotherapy and anti-VEGF treatment, FDA says
The Food and Drug Administration approved fruquintinib, sold as Fruzaqla by Takeda Pharmaceuticals, Inc., on November 8, 2023, for adult patients with metastatic colorectal cancer, according to the agency's announcement.
The approval applies to patients who previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy along with an anti-VEGF therapy.1 The FDA's notice also references an additional treatment requirement tied to RAS status, though the source text available does not spell out that condition in full.
The agency's announcement does not provide additional detail on the trial data, dosing, or regulatory pathway used for this approval. Readers should consult the full FDA prescribing information or announcement for complete eligibility criteria and supporting clinical evidence, as the available record here is partial.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.